(FOLD) Amicus Therapeutics - Ratings and Ratios
Enzyme,Replacement,Therapy,Gaucher,Fabry
FOLD EPS (Earnings per Share)
FOLD Revenue
Description: FOLD Amicus Therapeutics
Amicus Therapeutics Inc (NASDAQ:FOLD) is a biotechnology company listed on the NASDAQ exchange, operating within the biotechnology sub-industry. The companys stock is characterized by a market capitalization of approximately $1.95 billion, indicating a mid-cap status.
The stocks recent price movements suggest a level of volatility, as indicated by its Average True Range (ATR) of 3.25%. The beta of 0.505 implies that FOLDs stock price tends to be less volatile than the overall market. With a current price of $6.76, the stock is significantly below its 52-week high of $12.09 but above its 52-week low of $5.64.
From a fundamental analysis perspective, the companys negative Return on Equity (RoE) of -19.77% indicates that it has not been generating profits for its shareholders. The forward Price-to-Earnings (P/E) ratio of 49.02 suggests that investors are pricing in future earnings growth, despite the current lack of profitability. The absence of a trailing P/E ratio further underscores the companys current unprofitable status.
Key economic drivers for Amicus Therapeutics include the development and commercialization of its therapeutic products, particularly in the area of rare genetic diseases. The companys financial performance is likely to be influenced by factors such as research and development expenses, clinical trial outcomes, regulatory approvals, and market competition. Key Performance Indicators (KPIs) to watch include revenue growth, net income, cash burn rate, and pipeline development milestones.
To drive future growth, Amicus Therapeutics will need to successfully navigate the complex landscape of biotechnology product development, regulatory approvals, and market competition. Investors will be closely watching the companys ability to advance its pipeline, achieve commercial success, and ultimately drive profitability.
FOLD Stock Overview
| Market Cap in USD | 2,346m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2007-05-31 |
FOLD Stock Ratings
| Growth Rating | -58.8% |
| Fundamental | 45.6% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -41.2% |
| Analyst Rating | 4.42 of 5 |
FOLD Dividends
Currently no dividends paidFOLD Growth Ratios
| Growth Correlation 3m | 94.6% |
| Growth Correlation 12m | -86.6% |
| Growth Correlation 5y | -34.7% |
| CAGR 5y | -10.02% |
| CAGR/Max DD 3y | -0.16 |
| CAGR/Mean DD 3y | -0.48 |
| Sharpe Ratio 12m | -0.73 |
| Alpha | -51.76 |
| Beta | 0.979 |
| Volatility | 38.52% |
| Current Volume | 3394.1k |
| Average Volume 20d | 3423.6k |
| Stop Loss | 7.4 (-4.3%) |
| Signal | -1.29 |
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (-38.1m TTM) > 0 and > 6% of Revenue (6% = 34.3m TTM) |
| FCFTA -0.05 (>2.0%) and ΔFCFTA 5.62pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 64.84% (prev 64.44%; Δ 0.40pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.06 (>3.0%) and CFO -45.7m <= Net Income -38.1m (YES >=105%, WARN >=100%) |
| Net Debt (284.6m) to EBITDA (33.1m) ratio: 8.61 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.21 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (308.0m) change vs 12m ago 1.38% (target <= -2.0% for YES) |
| Gross Margin 90.37% (prev 88.45%; Δ 1.91pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 73.00% (prev 60.80%; Δ 12.21pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 0.53 (EBITDA TTM 33.1m / Interest Expense TTM 47.7m) >= 6 (WARN >= 3) |
Altman Z'' -12.68
| (A) 0.45 = (Total Current Assets 538.0m - Total Current Liabilities 167.6m) / Total Assets 815.3m |
| (B) -3.42 = Retained Earnings (Balance) -2.79b / Total Assets 815.3m |
| warn (B) unusual magnitude: -3.42 — check mapping/units |
| (C) 0.03 = EBIT TTM 25.2m / Avg Total Assets 782.4m |
| (D) -4.50 = Book Value of Equity -2.75b / Total Liabilities 611.0m |
| Total Rating: -12.68 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 45.55
| 1. Piotroski 2.50pt = -2.50 |
| 2. FCF Yield -1.49% = -0.74 |
| 3. FCF Margin -6.56% = -2.46 |
| 4. Debt/Equity 1.96 = 0.84 |
| 5. Debt/Ebitda 12.10 = -2.50 |
| 6. ROIC - WACC -5.14% = -6.43 |
| 7. RoE -19.77% = -2.50 |
| 8. Rev. Trend 95.33% = 4.77 |
| 9. Rev. CAGR 26.13% = 2.50 |
| 10. EPS Trend 83.33% = 2.08 |
| 11. EPS CAGR 46.49% = 2.50 |
What is the price of FOLD shares?
Over the past week, the price has changed by -3.13%, over one month by +4.46%, over three months by +27.77% and over the past year by -30.11%.
Is Amicus Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of FOLD is around 7.04 USD . This means that FOLD is currently overvalued and has a potential downside of -8.93%.
Is FOLD a buy, sell or hold?
- Strong Buy: 8
- Buy: 1
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the FOLD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 16.1 | 108.2% |
| Analysts Target Price | 16.1 | 108.2% |
| ValueRay Target Price | 7.9 | 1.6% |
Last update: 2025-09-13 04:35
FOLD Fundamental Data Overview
CCE Cash And Equivalents = 231.0m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 285.7143
P/S = 4.1069
P/B = 11.4814
P/EG = -0.18
Beta = 0.528
Revenue TTM = 571.2m USD
EBIT TTM = 25.2m USD
EBITDA TTM = 33.1m USD
Long Term Debt = 391.3m USD (from longTermDebt, last quarter)
Short Term Debt = 8.61m USD (from shortTermDebt, last quarter)
Debt = 399.9m USD (Calculated: Short Term 8.61m + Long Term 391.3m)
Net Debt = 284.6m USD (from netDebt column, last quarter)
Enterprise Value = 2.51b USD (2.35b + Debt 399.9m - CCE 231.0m)
Interest Coverage Ratio = 0.53 (Ebit TTM 25.2m / Interest Expense TTM 47.7m)
FCF Yield = -1.49% (FCF TTM -37.4m / Enterprise Value 2.51b)
FCF Margin = -6.56% (FCF TTM -37.4m / Revenue TTM 571.2m)
Net Margin = -6.67% (Net Income TTM -38.1m / Revenue TTM 571.2m)
Gross Margin = 90.37% ((Revenue TTM 571.2m - Cost of Revenue TTM 55.0m) / Revenue TTM)
Tobins Q-Ratio = -0.91 (set to none) (Enterprise Value 2.51b / Book Value Of Equity -2.75b)
Interest Expense / Debt = 2.89% (Interest Expense 11.6m / Debt 399.9m)
Taxrate = 21.0% (US default)
NOPAT = 19.9m (EBIT 25.2m * (1 - 21.00%))
Current Ratio = 3.21 (Total Current Assets 538.0m / Total Current Liabilities 167.6m)
Debt / Equity = 1.96 (Debt 399.9m / last Quarter total Stockholder Equity 204.3m)
Debt / EBITDA = 12.10 (Net Debt 284.6m / EBITDA 33.1m)
Debt / FCF = -10.68 (Debt 399.9m / FCF TTM -37.4m)
Total Stockholder Equity = 192.7m (last 4 quarters mean)
RoA = -4.67% (Net Income -38.1m, Total Assets 815.3m )
RoE = -19.77% (Net Income TTM -38.1m / Total Stockholder Equity 192.7m)
RoCE = 4.31% (Ebit 25.2m / (Equity 192.7m + L.T.Debt 391.3m))
RoIC = 3.41% (NOPAT 19.9m / Invested Capital 583.1m)
WACC = 8.55% (E(2.35b)/V(2.75b) * Re(9.62%)) + (D(399.9m)/V(2.75b) * Rd(2.89%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 90.91 | Cagr: 0.57%
Discount Rate = 9.62% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -37.4m)
EPS Correlation: 83.33 | EPS CAGR: 46.49% | SUE: 2.17 | # QB: True
Revenue Correlation: 95.33 | Revenue CAGR: 26.13%
Additional Sources for FOLD Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle